Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT03372057 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT03372057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03372057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Lead sponsor
SecuraBio
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2018
Completion date
December 22, 2023
Enrollment
156 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma